Rating Change
Canaccord Genuity analysts initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating on July 22, 2026.
new coverageNASDAQ:NKTR
Canaccord Genuity Initiates Coverage on Nektar Therapeutics (NKTR) with Buy
Rating Change Canaccord Genuity analysts initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating on July 22, 2026. Market Context Nektar Therapeutics operates in…
Market Context
Nektar Therapeutics operates in the Healthcare sector. The stock currently trades at $69.32 with a market capitalization of $1.0B.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Nektar Therapeutics.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Nektar Therapeutics
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 22, 2026 | Canaccord Genuity | Buy | N/A |
| May 11, 2026 | Wedbush | Neutral | N/A |
| May 08, 2026 | Piper Sandler | Overweight | N/A |
| Apr 21, 2026 | Citigroup | Buy | N/A |
| Apr 21, 2026 | Wedbush | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View NKTR Stock Page
Frequently Asked Questions
What does a Buy rating mean for NKTR?
A Buy rating from Canaccord Genuity reflects the analyst's outlook on Nektar Therapeutics (NASDAQ:NKTR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NKTR forecast page.